Description

How Mounjaro (Tirzepatide) Works
Mounjaro works by mimicking two hormones, GLP-1 and GIP, which play vital roles in controlling blood sugar and appetite. This dual-action mechanism increases insulin production, slows digestion, and reduces food cravings. It also lowers blood sugar spikes, benefiting both diabetes and weight management.
Key Benefits:
Improved Blood Sugar Control: Reduces high blood sugar by enhancing insulin release.
Appetite Suppression: Helps you feel fuller for longer, aiding in calorie reduction.
Weight Loss: Clinical studies show patients can lose up to 22.5% of their body weight with the maximum dose.

Dosage and Administration
Mounjaro is administered once weekly by subcutaneous injection (under the skin). It comes in pre-filled pens with varying doses from 2.5 mg to 15 mg.
Instructions for Use:
Inject into your abdomen, thighs, or upper arms.
Always use a new needle for each injection and dispose of it in a sharps bin.
Rotate injection sites each week to avoid irritation.
Store your pen in a refrigerator between 2°C and 8°C. Do not freeze.

Side Effects and Precautions
Common Side Effects:
Nausea
Diarrhoea
Vomiting
Constipation
Low blood sugar (especially when combined with other diabetes treatments like insulin)
These side effects are typically mild and improve as the body adjusts to the medication. However, some patients may experience more severe effects like dehydration, especially if nausea or vomiting persists.
Serious Side Effects:
Pancreatitis: Seek immediate medical help if you experience severe abdominal pain, particularly if it radiates to your back.
Allergic Reactions: Symptoms like difficulty breathing or swelling of the face, tongue, or throat require emergency attention.
Precautions:
Mounjaro is not suitable for those with a personal or family history of thyroid cancer.
It should be avoided in cases of severe gastrointestinal issues, including gastroparesis.
Women who are pregnant, planning to become pregnant, or breastfeeding should not use Mounjaro. Contraception is advised for women of childbearing age.

Eligibility Criteria
Mounjaro is prescribed to:
Adults with type 2 diabetes struggling to control blood sugar with other medications.
Adults with a BMI over 30 (obesity) or a BMI over 27 (overweight) with weight-related health conditions such as high blood pressure, high cholesterol, or prediabetes.
Patients must follow a healthcare provider’s advice on diet and exercise while using Mounjaro.

Frequently Asked Questions (FAQs)
1. How quickly will I see results with Mounjaro?
While Mounjaro starts working immediately, full effects on blood sugar and weight loss may take several weeks. Studies have shown noticeable weight loss after 72 weeks of treatment.
2. Can Mounjaro be used with other diabetes medications?
Yes, but combining Mounjaro with other treatments like insulin or sulfonylureas can increase the risk of low blood sugar. Always consult your healthcare provider to adjust other medications.
3. What should I do if I miss a dose?
If it’s within four days of your missed dose, take it as soon as you remember. If more than four days have passed, skip the dose and continue your regular schedule.
4. Is Mounjaro safe for long-term use?
Mounjaro is approved for long-term use for both diabetes management and weight loss. Your doctor will monitor you regularly to ensure the treatment remains effective and safe.
5. Can I stop taking Mounjaro if I reach my weight loss goals?
Yes, but stopping Mounjaro may lead to the return of hunger and increased blood sugar levels. Speak to your doctor before making any changes to your treatment.

Why Choose Mounjaro?
Mounjaro offers a comprehensive approach to managing type 2 diabetes and achieving weight loss. It has been proven effective in clinical trials, particularly for those who need both blood sugar control and weight reduction. By working on two key hormones, it provides superior outcomes compared to single-hormone treatments like Wegovy.

Important Regulatory Information for UK Patients
Mounjaro is prescription-only and is available via private healthcare providers.
As of November 2023, Mounjaro is not yet available through the NHS, but NICE is reviewing its approval for diabetes treatment. Recommendations for weight loss treatments under NHS guidance are expected by March 2024.
This medication is subject to additional monitoring in the UK, indicated by the black triangle symbol, to ensure its long-term safety.